Real-world outcomes of melanoma surveillance using the MoleMap NZ telemedicine platform.
J Am Acad Dermatol
; 85(3): 596-603, 2021 09.
Article
en En
| MEDLINE
| ID: mdl-32114083
ABSTRACT
BACKGROUND:
MoleMap NZ is a novel New Zealand-based store-and-forward telemedicine service to detect melanoma. It uses expert review of total body photography and close-up and dermoscopic images of skin lesions that are suspicious for malignancy.OBJECTIVE:
The purpose of this study was to assess the effectiveness of MoleMap NZ as a melanoma early detection program.METHODS:
We conducted a review of 2108 melanocytic lesions recommended for biopsy/excision by MoleMap NZ dermoscopists between January 2015 and December 2016.RESULTS:
Pathologic diagnoses were available for 1571 lesions. Of these, 1303 (83%) lesions were benign and 260 (17%) lesions were diagnosed as melanoma, for a melanoma-specific benignmalignant ratio of 5.01. The number needed to biopsy to obtain 1 melanoma was 6. Among melanomas with available tumor thickness data (n = 137), 92% were <0.8 mm (range in situ to 3.1 mm), with in situ melanomas comprising 74%.LIMITATIONS:
Only lesions recommended for excision were analyzed. Pathology results were available for 75% of these cases. Tumor thickness data were available for 53% of melanomas diagnosed.CONCLUSIONS:
This real-world study of MoleMap NZ, a community-based teledermoscopy program, suggests that it has the potential to increase patients' access to specialist expertise via telemedicine. Additional studies are needed to more accurately define its efficacy.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Telemedicina
/
Melanoma
Tipo de estudio:
Screening_studies
País/Región como asunto:
Oceania
Idioma:
En
Revista:
J Am Acad Dermatol
Año:
2021
Tipo del documento:
Article